Skip to search formSkip to main contentSkip to account menu

ABT-510

Known as: ABT 510, ABT510 
A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.
Review
2009
Review
2009
A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
2023 Background: ABT-510 (Abbott Laboratories, Abbott Park, IL, USA) is a Thrombospondin-1 (TSP-1) mimetic drug with anti… 
2007
2007
A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors
3541 Background: BV is a potent inhibitor of vascular endothelial growth factor (VEGF) with broad clinical activity both alone… 
2006
2006
A phase II study of ABT-510 for the treatment of metastatic melanoma.
8041 Background: ABT-510 is a synthetic peptide analog of thrombospondin-1 demonstrating inhibition of VEGF/bFGF mediated human… 
2005
2005
A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS)
9013 Background: ABT-510 is a 9-amino acid peptide that mimics the antiangiogenic activity of the naturally occurring protein… 
2005
2005
ABT-510 oncolytic angiogenesis inhibitor
Thrombospondin-1 (TSP-1) is secreted by most epithelial cells and acts as a multifunctional inhibitor of angiogenesis. It has… 
2005
2005
A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma
4607 Background: ABT-510 is a potent nonapeptide that mimics the antiangiogenic activity of the naturally occurring protein… 
2004
2004
Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer.
3077 Background: Thrombospondin-1 is a naturally occurring angiogenesis inhibitor. ABT-510, a thrombospondin-mimetic peptide that… 
2004
2004
Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects.
3080 Background: ABT-510 is a subcutaneously (SC) administered nonapeptide thrombospondin analogue in phase 2 clinical… 
2002
2002
A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (ABT-510) in patients with advanced cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)